Gapping up
In reaction to strong earnings/guidance:
- QIWI +10.5%, TRQ +9.4%, MMYT +7.4%, NICE +3.8%, NTES +3.6%, FLO +3.6%, CSCO +3.4%, WMT +1.4%, ALC +0.9%, JACK +0.5%
Other news:
- IOVA +25.1% (updates from ongoing clinical trials including new interim data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and with TIL therapy lifileucel in advanced melanoma)
- MGNX +14.6% (SOPHIA phase 3 breast cancer ASCO abstract released)
- AGIO +13.1% (announces that Phase 3 ClarIDHy trial of TIBSOVO achieved its primary endpoint)
- CHRA +11.9% (after closing 40% lower on the day)
- NTEC +8.9% (research collaboration agreement with Merck)
- VSTM +3.9% (light volume; to present new COPIKTRA dose modification data from patients treated in the Phase 3 DUO study - dose interruptions of a median 15 days do not significantly impact response or PFS)
- CFX +2.7% (to sell Air and Gas Handling business to KPS Capital Partners for enterprise value of $1.80 bln)
- MRNA +1.3% (ASCO abstract on mRNA-4157 in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors released)
- DRE +0.8% initiated with Buy at Goldman)
- AMZN +0.7% (Buffett's Berkshire affirms new Amazon holding)
Analyst comments:
- STNG +1.6% (upgraded to Overweight from Neutral at JP Morgan)
- M +0.5% (upgraded to Neutral from Sell at Goldman)